Research Topics
Genomes and Genes | Douglas M PotterSummaryAffiliation: University of Pittsburgh Country: USA Publications
| Collaborators
|
Detail Information
Publications
Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancerDouglas M Potter
University of Pittsburgh, University of Pittsburgh Cancer Institute, Biostatistics Facility, Suite 325, Sterling Plaza, 201 North Craig St, PA 15213, USA
Stat Med 21:1805-23. 2002..4 on a target DLT probability of 0.3 is obtained over a wide variation in dose-response characteristics of the study drug. The performance of the new method is compared to that of rule-based methods...- Phase I studies of chemotherapeutic agents in cancer patients: a review of the designsDouglas M Potter
Biostatistics Department, Graduate School of Public Health, University of Pittsburgh and Biostatistics Facility, Cancer Institute, Pennsylvania 15213, USA
J Biopharm Stat 16:579-604. 2006..Rule-based designs can always determine a reasonable maximum tolerable dose based on observed toxicity, but when model assumptions are not satisfied, many model-guided designs will not... - Omnibus permutation tests of the overall null hypothesis in datasets with many covariatesDouglas M Potter
Biostatistics Department, Graduate School of Public Health, University of Pittsburgh and Biostatistics Facility, University of Pittsburgh Cancer Institute, PA 15213, USA
J Biopharm Stat 16:327-41. 2006..We use simulations to investigate seven omnibus test statistics and find that the Anderson-Darling and Fisher's statistics are superior to the others... - Omnibus permutation tests of the association of an ensemble of genetic markers with disease in case-control studiesDouglas M Potter
Biostatistics Department, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Genet Epidemiol 30:438-46. 2006.... - A permutation test for inference in logistic regression with small- and moderate-sized data setsDouglas M Potter
Biostatistics Department, Graduate School of Public Health, and Biostatistics Facility, University of Pittsburgh Cancer Institute, University of Pittsburgh, Suite 325, Sterling Plaza, 201 North Craig Street, Pittsburgh, PA 15213, USA
Stat Med 24:693-708. 2005.... 
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignanciesSuresh S Ramalingam
Authors Affiliations Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Clin Cancer Res 14:3456-61. 2008..We conducted a phase I study in patients with advanced malignancies to determine the recommended phase II dose of the combination of 17-AAG and paclitaxel...- Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignanciesRamesh K Ramanathan
Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Cancer Chemother Pharmacol 55:354-60. 2005..To improve the therapeutic index, we evaluated a weekly regimen of docetaxel in combination with capecitabine, and determined the maximum tolerated dose, toxicities and pharmacokinetics of this combination... - AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patientsViktoria N Evdokimova
Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
J Immunother 30:425-37. 2007..Importantly, CD4 T-cell cytokine expression profiles were skewed towards interleukin-2 and interferon-gamma production when activated by adenovirally engineered DC, which has therapeutic implications for vaccination efforts... - Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancersRamesh K Ramanathan
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
Clin Cancer Res 13:1769-74. 2007..The primary objective was to establish the dose-limiting toxicity (DLT) and recommended phase II dose of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) given twice a week... - Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanomaLisa H Butterfield
Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
J Immunother 31:294-309. 2008..Responses in CD8+ and CD4+ T cells to additional antigens were noted in 2 patients. The AdVMART1-transduced DC vaccine was safe and immunogenic in patients with metastatic melanoma... - Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumorsLaura L Jung
Molecular Therapeutics and Drug Discovery Program, University of Pittsburgh Cancer Institute, PA 15213, Pittsburgh, USA
Cancer Chemother Pharmacol 54:487-96. 2004..97, respectively. The recovery of 9NC and 9AC in the urine was <15%. CONCLUSIONS: There was significant interpatient and intrapatient variability in the disposition of 9NC and 9AC. 9NC and 9AC undergo primarily nonrenal elimination... 
Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirusLazar Vujanovic
Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
Cancer Immunol Immunother 58:121-33. 2009..These data identify molecular changes in AdV-transduced DC (AdV/DC) that could influence T cell priming and should be considered in design of cancer vaccines...- Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignanciesSuresh S Ramalingam
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Clin Cancer Res 13:3605-10. 2007..The primary objective of this study was to determine the recommended phase II doses of the novel histone deacetylase inhibitor vorinostat when administered in combination with carboplatin and paclitaxel... - Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancerBenedito A Carneiro
University of Pittsburgh Cancer Institute, PA 15232, USA
Clin Colorectal Cancer 11:53-9. 2012..Irinotecan and weekly cetuximab (I+C) is a standard second-line regimen for metastatic colorectal cancer (mCRC). This study investigated the safety and efficacy of every 2 weeks I+C in patients with mCRC... - Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1Ryo Ueda
Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Proc Natl Acad Sci U S A 106:10746-51. 2009..This study suggests development of novel miR-targeted therapy to promote cytolysis of tumor cells... - Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancerLisa H Butterfield
Department of Medicine, Surgery and Immunology University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA
Cancer Immunol Immunother 56:1931-43. 2007.... - Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypesWilliam C Zamboni
Hillman Cancer Research Center, Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
Invest New Drugs 24:393-401. 2006..The aim of this study was to evaluate the functional consequence of known single nucleotide polymorphisms in the transporter genes ABCB1, ABCC2, and ABCG2 on the pharmacokinetic disposition of 9NC and 9AC... - Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumorsWilliam C Zamboni
Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
Clin Cancer Res 10:5058-64. 2004..In an effort to increase the dose administered per day and determine whether the daily dose or number of days of treatment influence toxicity, we performed a Phase I study of 9NC using intermittent schedules of administration... - Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancersRamesh K Ramanathan
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Cancer Chemother Pharmacol 57:465-74. 2006..The pharmacokinetics of MGd were also evaluated... - Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancerYang Liu
Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
J Immunol 177:712-21. 2006..These subdominant epitope-specific T cells can also recognize tumor cells and may be important therapeutically... - Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancersRamesh K Ramanathan
Molecular Therapeutics Drug Discovery Program, Biostatistics Department, Graduate School of Public Health, and Biostatistics Facility, University of Pittsburgh Cancer Institute, PA 15232, USA
Clin Cancer Res 11:3385-91. 2005..We did a phase I study of 17AAG to establish the dose-limiting toxicity and maximum tolerated dose and to characterize 17AAG pharmacokinetics and pharmacodynamics... - A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancerRajesh Sehgal
University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
Clin Colorectal Cancer 10:117-20. 2011..A week on/week off capecitabine schedule with oxaliplatin/bevacizumab was evaluated in patients with metastatic colorectal cancer (mCRC)... - Cytokine gene therapy using adenovirally transduced, tumor-seeking activated natural killer cellsStephen R Goding
Department of Immunology, Graduate School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
Hum Gene Ther 18:701-11. 2007..These data show that the presence of IL-12 around tumor-infiltrating A-NK cells enhances their antitumor activity while reducing their requirement for systemically administered IL-2... - Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in Hideho Okada
G12 a Research Pavilion at the Hillman Cancer Center, 5117 Centre Ave, Pittsburgh, PA 15213 1863, USA
J Clin Oncol 29:330-6. 2011..GAAs for these peptides are EphA2, interleukin (IL)-13 receptor-α2, YKL-40, and gp100... - Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumorsKotaro Sasaki
Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Cancer Res 67:6451-8. 2007.... - Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patientsDouglas M Potter
Biostatistics Facility, University of Pittsburgh Cancer Institute, 201 North Craig Street, Suite 325, Pittsburgh, PA 15213, United States
J Immunol Methods 376:108-12. 2012..We describe a new study of the association of serum biomarker level with overall survival in melanoma patients, and the problems encountered in carrying it out... - Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomasHideho Okada
Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
J Transl Med 5:67. 2007..The prognosis for malignant gliomas remains dismal. We addressed the safety, feasibility and preliminary clinical activity of the vaccinations using autologous glioma cells and interleukin (IL)-4 gene transfected fibroblasts... - Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy BiomarkersLisa H Butterfield
Department of Medicine, University of Pittsburgh, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
Clin Cancer Res 17:3064-76. 2011..Despite substantial effort, we do not yet know which parameters of antitumor immunity to measure and which assays are optimal for those measurements... - A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"Lisa H Butterfield
Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
J Transl Med 6:81. 2008..This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document... - Multiplex serum biomarker assessments: technical and biostatistical issuesLisa H Butterfield
University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
J Transl Med 9:173. 2011..Many of these studies seek biomarkers among circulating proteins accessed in blood. Many levels of standardization in materials and procedures have been identified which can impact the resulting data... - Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxelJosephia R Muindi
Center for Clinical Pharmacology and Cancer Institute, University of Pittsburgh, PA 15213, USA
Clin Pharmacol Ther 72:648-59. 2002..An additional goal was to evaluate the relationship between calcitriol dose and hypercalcemia... - Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancerAnn Willman Silk
University of Pittsburgh, School of Medicine and Clinical Scientist Training Program, Pittsburgh, PA 15232, United States
Mol Immunol 47:52-6. 2009..045 OD vs. 0.030 OD; p=0.017). Our data support further studies into the potential role of anti-MUC1 immunity in preventing progression of premalignant colon lesions to colon cancer... - Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatinWilliam C Zamboni
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
Clin Cancer Res 8:2992-9. 2002..There was no relationship between Factor VIII expression and Pt exposure in tumors. The variable penetration of Pt from plasma into tumor ECF may be associated with variable response of tumors... - MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility studyTakashi Kimura
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
Cancer Prev Res (Phila) 6:18-26. 2013..g., high levels of MDSC) might already exist in some individuals, suggesting an even earlier premalignant stage or preselection of nonimmunosuppressed patients for prophylactic vaccination... - Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanomaWilliam C Zamboni
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15213, USA
Cancer Chemother Pharmacol 53:329-36. 2004..Thus, we evaluated the disposition of encapsulated and released Pt in plasma and tumors after administration of STEALTH liposomal and nonliposomal cisplatin... - Prevention of mammary carcinogenesis in MMTV-neu mice by cruciferous vegetable constituent benzyl isothiocyanateRenaud Warin
Department of Pharmacology, and University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Cancer Res 69:9473-80. 2009..The present study demonstrating efficacy of BITC against mammary cancer in an animal model provides impetus to determine its activity in a clinical setting... - Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccinesHideho Okada
Departments of Neurological Surgery, University of Pittsburgh School of Medicine, PA 15213, USA
Cancer Res 64:5830-8. 2004..On the basis of these results, we believe that local expression of IFN-alpha by DCs within the intracranial tumor site may enhance the clinical efficacy of peripheral vaccine approaches for brain tumors... - A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptidesLisa H Butterfield
Department of Medicine, Surgery and Immunology, Hillman Cancer Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA
Clin Cancer Res 12:2817-25. 2006..We conclude that the human T cell repertoire is capable of responding to the AFP self antigen after the administration of AFP peptide-pulsed DC even in an environment of high circulating levels of this oncofetal antigen... - Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patientsRamesh K Ramanathan
University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
J Clin Oncol 20:4313-8. 2002..To determine whether granulocyte-macrophage colony-stimulating factor (GM-CSF) would improve response to influenza vaccination in cancer patients... - DNA repair pathways involved in anaphase bridge formationCeyda Acilan
Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA
Genes Chromosomes Cancer 46:522-31. 2007..Moreover, intrinsic NHEJ activity of different cell lines appears to have a positive trend with induction of bridges from DNA damage... - Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working GroupRamesh K Ramanathan
Translational Genomics Research Institute, 13208 E Shea Blvd, Ste 100, Scottsdale, AZ 85259, USA
J Clin Oncol 26:563-9. 2008..To develop dosing guidelines and to evaluate the pharmacokinetics of imatinib in patients with liver dysfunction (LD)... - Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulationJosephia R Muindi
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
Cancer Chemother Pharmacol 56:492-6. 2005..83). We conclude that the commercially available liquid 1,25-D(3) formulation offers no PK advantage over caplet formulation... - Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancerDonald L Trump
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
Cancer 106:2136-42. 2006..The combination of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) plus dexamethasone was studied based on evidence that dexamethasone potentiates the antitumor effects of calcitriol and ameliorates hypercalcemia... - Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysisChris Kahlenborn
Department of Internal Medicine, Altoona Hospital, Altoona, PA, USA
Mayo Clin Proc 81:1290-302. 2006..To perform a meta-analysis of case-control studies that addressed whether prior oral contraceptive (OC) use is associated with premenopausal breast cancer... - Variability in cerebral oxygen delivery is reduced in premature neonates exposed to chorioamnionitisToby D Yanowitz
Department of Pediatrics, University of Pitttsburgh School of Medicine, PA 15217, USA
Pediatr Res 59:299-304. 2006..Further studies are needed to determine how these findings relate to cerebral blood flow autoregulation and oxygen utilization in premature infants...